Protagonist Free Cash Flow from 2010 to 2024
| PTGX Stock | USD 43.17 3.33 7.16% |
Free Cash Flow | First Reported 2015-03-31 | Previous Quarter 268.6 M | Current Value -28.6 M | Quarterly Volatility 47.6 M |
Check Protagonist Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protagonist Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.5 M, Interest Expense of 4.1 M or Selling General Administrative of 18 M, as well as many indicators such as Price To Sales Ratio of 20.61, Dividend Yield of 0.0 or PTB Ratio of 4.06. Protagonist financial statements analysis is a perfect complement when working with Protagonist Therapeutics Valuation or Volatility modules.
Protagonist | Free Cash Flow |
Latest Protagonist Therapeutics' Free Cash Flow Growth Pattern
Below is the plot of the Free Cash Flow of Protagonist Therapeutics over the last few years. It is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets. Protagonist Therapeutics' Free Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protagonist Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Free Cash Flow | 10 Years Trend |
|
Free Cash Flow |
| Timeline |
Protagonist Free Cash Flow Regression Statistics
| Arithmetic Mean | (40,743,417) | |
| Geometric Mean | 23,896,816 | |
| Coefficient Of Variation | (94.00) | |
| Mean Deviation | 32,507,778 | |
| Median | (30,351,000) | |
| Standard Deviation | 38,300,423 | |
| Sample Variance | 1466.9T | |
| Range | 112.2M | |
| R-Value | (0.84) | |
| Mean Square Error | 459.2T | |
| R-Squared | 0.71 | |
| Significance | 0.000082 | |
| Slope | (7,212,935) | |
| Total Sum of Squares | 20536.9T |
Protagonist Free Cash Flow History
Other Fundumenentals of Protagonist Therapeutics
Protagonist Therapeutics Free Cash Flow component correlations
About Protagonist Therapeutics Financial Statements
Protagonist Therapeutics investors use historical fundamental indicators, such as Protagonist Therapeutics' Free Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protagonist Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Free Cash Flow | -70.8 M | -74.4 M | |
| Free Cash Flow Yield | (0.05) | (0.06) | |
| Free Cash Flow Per Share | (1.25) | (1.31) | |
| EV To Free Cash Flow | (15.75) | (14.97) | |
| Price To Free Cash Flows Ratio | (18.37) | (17.45) | |
| Free Cash Flow Operating Cash Flow Ratio | 1.01 | 0.80 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Protagonist Stock Analysis
When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.